Ireland's Chanelle Pharma acquired by private equity firm for estimated €300M

Chanelle Pharma, an Irish pharmaceutical company specializing in generics for both human and animal health, was recently acquired by Exponent, a UK private equity firm, for an estimated €300 million. This acquisition highlights the significant value and potential for growth in the generics market. Chanelle Pharma's integration into Exponent's portfolio is expected to expand its operational capabilities, enhance product offerings, and potentially drive innovations within the pharmaceutical industry.

“The business has established itself as a leading pharmaceutical manufacturer of both veterinary and medical products with an extensive portfolio of licenses,” James Gunton, a partner at Exponent, said in the release. “We see tremendous opportunity in the development pipeline and look forward to bringing new products to market, as well as continuing to invest in Research and Development in the years to come.”

To date, Exponent has invested more than 1 billion euros in Irish companies. A timeline for closing the Chanelle deal wasn’t disclosed.Michael Burke, founder and managing partner of Chanelle, will retire from the company when the deal is completed.